


PHARMACEUTICAL 2021

Metacrine Inc. Rank 171 of 409





PHARMACEUTICAL 2021

Metacrine Inc. Rank 171 of 409

The relative strengths and weaknesses of Metacrine Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Metacrine Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 280% points. The greatest weakness of Metacrine Inc. is the variable Net Income, reducing the Economic Capital Ratio by 93% points.

The company's Economic Capital Ratio, given in the ranking table, is -76%, being 278% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	102,023
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,026
Liabilities, Non-Current	0
Other Assets	1,579
Other Compr. Net Income	-40
Other Expenses	0
Other Liabilities	0
Other Net Income	-614
Property and Equipment	634
Research and Development	26,790
Revenues	0
Selling, General and Administrative Expense	9,900

Output Variable	Value in 1000 USD
Assets	104,236
Liabilities	4,026
Expenses	36,690
Stockholders Equity	100,210
Net Income	-37,304
Comprehensive Net Income	-37,324
Economic Capital Ratio	-76%